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Background: Diagnostic bronchial biopsy samples from lung can-
cer patients may be used for molecular biologic analyses to help
select therapy and provide prognostic information. Some have sug-
gested that direct molecular analysis of bronchial biopsy fragments
may be feasible, bypassing histologic examination. We analyzed a
series of 100 bronchial biopsy specimens in lung cancer patients to
assess the frequency and quantity of tumor present in biopsy samples.
Methods: The proportion of tumor in bronchial biopsy specimens
was assessed by measuring the tumor area in histologic sections
using computer-aided morphometry.
Results: In only 48% of cases did all the biopsy fragments contain
some tumor. The median number of fragments obtained at bronchos-
copy was 4; median number actually containing tumor was 3. The mean
total surface area of tumor (as a percentage of the total sample area) in
biopsy fragments was, for all cases, 33.4%; median area 28%. Biopsies
with small cell carcinoma had more tumor (mean area 46.5%, median
49%; p  0.0006) than all other non-small cell carcinoma cases.
Conclusion: Malignant bronchial biopsy samples frequently contain
limited amounts of primary carcinoma. Often, one or more of the
biopsy fragments will not contain tumor. This has important impli-
cations for the storage and use of bronchial biopsy samples for
genetic analysis.
Key Words: Lung cancer, Quantitation, Bronchial biopsy, Predic-
tive markers, Molecular biology.
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New therapies are emerging to treat advanced primarylung cancer, especially non-small cell lung cancers
(NSCLCs). Mutational analysis of lung cancer genes, partic-
ularly of the epidermal growth factor receptor and KRAS, has
been used to identify likely responders to tyrosine kinase
inhibitors1–4 and to provide prognostic information. Other
emerging predictive tests include the use of quantitative
polymerase chain reactions to assess mRNA levels in a
number of different genes such as ERCC1, BRCA1, RRM1,
and Serpin B3.5,6 Recently, it has been suggested that sam-
pling of tissue biopsy specimens from bronchoscopy, bypass-
ing the process of histologic study, may be sufficient for
DNA isolation and mutational analysis.7 In this model, it is
assumed that paired samples taken from a tumor at the time
of bronchoscopy will both contain representative amounts of
malignant tissue, and that if the histology of one fragment
confirms the presence of tumor, it can safely be assumed that
mutational analysis of the second, unprocessed fragment, will
reflect the genetic profile of the patient’s tumor.
In a recent editorial, Tsao8 discussed the potential
problems that may arise from such analyses. It was argued
that treatment decisions made on the basis of mutational
results from samples without histologic confirmation might
not be sound. Tumor tissue is composed of a complex
mixture of neoplastic and nonneoplastic cells. In addition,
tissue fragments obtained at bronchoscopy are often a heter-
ogeneous collection of tissue types, including entirely benign
bronchial mucosa, reactive inflammatory or fibrotic tissue as
well as tumor.
Anecdotal experience suggests that in many bronchial
biopsy samples, the amount of actual tumor is limited, both in
terms of the number of biopsy fragments containing any
tumor and the proportion of the sample that consists of
carcinoma. This study was designed to quantify these factors
in bronchial biopsy specimens containing primary carcinoma.
PATIENTS AND METHODS
One hundred consecutive cases of primary carcinoma
of the lung diagnosed by bronchial biopsy were obtained
from the records of the Department of Pathology, Aberdeen
Royal Infirmary. All biopsies were performed over a period
during 2004. In 98 cases, the patients underwent flexible
bronchoscopy, carried out by the hospital’s team of 8 respi-
ratory physicians. Two patients had a surgical rigid broncho-
scopic procedure. The endoscopic findings were provided to
the pathologist by the submitting physician on the specimen
request form. These data were recorded for each sample.
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The original diagnostic hematoxylin and eosin-stained
sections were retrieved from the departmental files and re-
viewed. The number of tissue fragments in the sample and the
number showing tumor were recorded. The final histologic
diagnosis was recorded together with any use of immunohis-
tochemistry or other special staining techniques for the pur-
poses of diagnosis.
Computer-aided digital morphometry was used to mea-
sure tumor area. This was performed using a “Color View-II”
digital camera (Soft Imaging Systems GmbH, Munster, Ger-
many) that was attached to an Olympus BX41 light micro-
scope. Digital images of the biopsies were captured at low
power using a 2 lens and then analyzed using “AnalySIS”
software (Soft Imaging Systems). Total tissue area, which
included tissue fragments devoid of tumor, and total tumor
area were calculated, and the tumor area was expressed as a
percentage of the total tissue area.
Statistical analysis of data was undertaken using the
PRISM software statistical package using analysis of vari-
ance or Mann-Whitney tests where appropriate.
RESULTS
The general characteristics of the patients and their
tumors are shown in Table 1. Squamous cell carcinoma was
the dominant specific tumor type diagnosed on bronchial
biopsy (39% of cases), followed by small cell lung carcinoma
FIGURE 1. Histogram showing mean proportion of tumor
in bronchial biopsy samples for different tumor cell types. p
values expressed are for calculations based on mean values
of tumor area. *The difference in median tumor area be-
tween non-small cell lung cancer, not otherwise specifiable
(NSCLC, NOS) and adeno and squamous cell carcinomas is
significant (p  0.05).
TABLE 1. Characteristics of Patients and Tumor Histology
Number of patients 100
Gender
Male 57
Female 43
Age (yr)
Mean 67.6
Range 51–83
Histological diagnosis
Adenocarcinoma 11
Squamous 39
Small cell carcinoma 28
Other 2
Non-small cell carcinoma, NOSa 20
In the “other” category, one case was considered large cell neuroendocrine carci-
noma and the other was an adenoid cystic carcinoma.
a “Non-small cell carcinoma, NOS” refers to non-small cell carcinoma, not other-
wise specifiable on the bronchial biopsy specimen.
TABLE 2. Flexible Bronchoscopic Biopsy Samples: Tissue Fragment Numbers, Area of Sample (%) Replaced by Tumor, and
Histological Type
All Cases Small Cell All NSCLC Adenocarcinoma Squamous Non-small Cell, NOS
No. of cases 98 28 70 11 37 20
Total no. of fragments
Mean (range) 3.9 (1–14) 3.4 (1–5) 4.2 (1–14) 4.6 (3–8) 4.1 (1–14) 3.9 (1–7)
Median number 4 4 4 4 4 4
Sum 386 96 290 51 152 79
Fragments with tumor
Mean (range) 2.8 (1–8) 2.9 (1–5) 2.7 (1–8) 3.3 (1–6) 2.8 (1–8) 2.0 (1–5)
Median number 3 3 2 3 2 2
Sum 272 83 189 36 105 40
Area of tumor
Mean (range) 33.4% (0.1–94) 46.5% (0.1–90) 28.2% (0.1–94) 32.1% (3–94) 31.1% (1–89) 19.6% (0.1–74)
Median 28% 49% 22% 23% 27% 10%
The “all NSCLC” group includes the adenoid cystic and large cell neuroendocrine carcinoma case.
NSCLC, non-small cell lung cancer; NOS, not otherwise specifiable.
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(28%) and adenocarcinoma (11%). A single case each of
adenoid cystic carcinoma and of large cell neuroendocrine
carcinoma was found. In 20% of cases, a diagnosis of
“non-small cell carcinoma” was made, but it was not possible
to specify the cell type any further (NSCLC, NOS [not
otherwise specifiable]).
An endobronchial mass was observed in 69 patients at
bronchoscopy, mucosal abnormalities were noted in 12 pa-
tients, 11 had airway compression, and 7 patients had a
combination of features at bronchoscopy. In a single case, the
findings were not recorded.
The median number of tissue biopsy fragments re-
trieved bronchoscopically for all samples studied was 4. The
median number of fragments actually containing tumor was 3
for all studied cases. It was also 3 for cases of small cell
carcinoma and adenocarcinoma but 2 for all NSCLC cases,
squamous cell carcinoma, and NSCLC, NOS cases. The two
biopsy samples taken at rigid bronchoscopy both showed
squamous cell carcinoma in higher than average amounts
(37% and 69%). These were excluded from the further
analysis of tumor areas. The mean/median % tumor for each
tumor subtype in the 98 cases derived from flexible bron-
choscopy was consistently below 50% (Table 2). For all
cases, the mean area of the sample occupied by tumor was
33.4%, whereas the median value was 28%. Small cell
carcinoma was present in significantly greater amounts (mean
46.5%, median 49%; p  0.0006) than in all types of
non-small cell carcinoma (mean 28.2%, median 22%) (Figure
1). Significantly, less tumor was present when a diagnosis of
NSCLC, NOS was made (mean 19.6%, median 10%; p 
0.05) when compared with other tumor diagnoses. Squamous
carcinoma occupied an average of 31.1% of biopsy area
(median 27%), whereas adenocarcinoma was found in similar
amounts (mean 32.1%, lower median value of 23%). Bron-
FIGURE 2. Histograms for each cell type cate-
gory, showing the distribution of tumor pro-
portion in all the cases studied. The bar marks
the median value for tumor area for each his-
tologic category.
Coghlin et al. Journal of Thoracic Oncology • Volume 5, Number 4, April 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer450
chial biopsy samples containing squamous or adenocarci-
noma, as a group, showed significantly less tumor (mean tumor
area) when compared with small cell carcinoma samples (p 
0.05). Bronchial biopsy samples containing squamous or ade-
nocarcinoma, as a group, had a higher median tumor area than
the NSCLC, NOS group (P 0.05); comparison of mean areas
failed to reach significance (Figures 1 and 2).
Overall, in those cases where immunohistochemistry
was used for diagnostic purposes (13 cases), there was no
statistical difference in the amount of tumor present (mean
area 39%, median 28%) when compared with those cases
diagnosed using only the hematoxylin and eosin-stained sec-
tions (mean area 33%, median 28%).
In biopsy samples taken at flexible bronchoscopy from
visible tumors (72 cases), the mean tumor area was 34.7%
(median 30%), whereas in those where endobronchial tumor
was not seen (25 cases), the values were a mean of 29.4% and
a median of 19%. Although this would seem to be a plausible
difference, reflecting better tumor sampling in the context of
a visible endobronchial mass, these differences were not
statistically significant (p  0.20).
DISCUSSION
Approximately 80% of patients with lung cancer have
unresectable tumor at presentation. For those who are fit
enough, chemotherapy is the appropriate treatment choice.
Increasingly, therapeutic decisions are made in a selective
manner, tailoring therapy according to specific patient and
tumor characteristics. In patients with advanced disease, de-
tailed assessment of gene mutations, fluorescence in situ
hybridization tests for gene amplification, quantitative poly-
merase chain reaction for specific gene mRNA levels, or
marker immunohistochemistry may be used to inform the
choice of treatment. Therapeutic decisions for first and sub-
sequent treatments are likely to be made on the diagnostic
biopsy sample, because this is usually the only material
available for testing.
This study has shown that the amount of tumor in
specimens obtained at flexible bronchoscopy is relatively
low. For all tumor types, the mean % area of tumor in a
biopsy sample was 33.4% and for NSCLC overall as a group
it was 28%. In addition, tumor was not represented in every
fragment retrieved from the biopsy site. Indeed, the number
of cases in which all the fragments submitted actually con-
tained tumor was less than half (48%). The nontumor ele-
ments that were measurable in this study comprised obvious
areas of tumor stroma plus surrounding normal bronchial
mucosal tissues. The measurements could not account for
those nonneoplastic cellular elements such as capillary endo-
thelial cells, inflammatory cells, and isolated fibroblasts inti-
mately admixed with the tumor cells. Thus, our measure-
ments will slightly underestimate the nonneoplastic
composition of the biopsy samples (Figures 3 and 4). No
similar data on bronchial biopsy samples have been found in
the literature. Comparable work done on prostate core biop-
sies9,10 correlated tumor representation in core biopsies with
tumor volume in prostatectomy specimens and consequently
with prognosis. As with bronchial biopsy samples, in these
core biopsies, the amount of tumor present showed a very
wide range; not infrequently tumor volume was limited. In
one such study, prostatic needle core biopsies contained a
surface area of tumor ranging from less than 5% in one-third
of patients to 90% (mean 16%, median 10%).9
FIGURE 3. This particular tissue fragment from a bronchial
biopsy sample comprises tumor devoid of surrounding
stroma or normal adjacent bronchial mucosal elements. For
the purposes of tumor area measurement, this particular
fragment would be considered 100% tumor. Of course,
even in this fragment, there are scattered capillary endothe-
lial cells, fibroblasts, and inflammatory cells admixed with
the tumor. These were ignored in our measurements, yet
would still contribute nontumor DNA or RNA to any tissue
extract.
FIGURE 4. In this particular image there are three tissue
fragments and a cluster of stripped bronchial epithelial cells.
All contain nucleated cells that would contribute DNA to any
extracted sample from this specimen. Only the largest frag-
ment (bottom right) contains tumor, the smaller fragments
do not. By area, the tumor accounts for only about 7% of
the viable cellular tissue in this image. Most of the tissue
present is nonneoplastic bronchial mucosal connective tis-
sue, smooth muscle, and respiratory epithelium.
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Our data represent the practice of a single group of
experienced physician bronchoscopists in a single center
practicing standard white-light flexible bronchoscopy and is
thus a relatively homogeneous case cohort. The trend of
relatively more tumor in biopsy samples from visible endo-
bronchial lesions, as opposed to those causing extrinsic com-
pression, would be expected. Despite the substantial differ-
ence in median values, our data failed to show a statistical
difference; the number of cases lacking an endobronchial
mass was relatively small. Furthermore, the relatively large
amounts of tumor seen in small cell carcinoma when com-
pared with the various NSCLCs is expected given the greater
tendency for more bulky and more central (therefore more
often endoscopically visible and easily targeted) disease in
small cell carcinoma. With regard to the NSCLC cases,
squamous carcinoma was, as expected in a cohort of cancers
diagnosed at bronchoscopy, most frequent. Most adenocarci-
nomas are peripheral tumors, less often accessible at bron-
choscopy but when so, possibly a reflection of more advanced
disease spreading to involve a central bronchus. This ac-
counts both for the smaller number of cases of adenocarci-
noma in this series and the slightly smaller tumor volumes
present in those samples; not infrequently adenocarcinoma
manifests in bronchial biopsy samples as mucosal lym-
phangitic spread of tumor. Tumors are designated “NSCLC,
NOS” in some biopsy material where there are insufficient
histologic features present to enable a more specific subtype
diagnosis of, for example, squamous or adenocarcinoma. It is
likely that the designation of “NSCLC, NOS” in those cases
in this study is, at least in part, a reflection of lower volumes
of tumor in these samples. The use of immunohistochemistry
in bronchial biopsy sample diagnosis does not seem, at least
in this study, to be a direct result of low tumor volume in the
sample. It is worth noting, however, that the extra “consump-
tion” of tumor, when extra immunohistochemistry is ordered
for the purposes of securing the diagnosis, will result in less
of an already limited resource remaining for predictive
marker testing.
CONCLUSION
The findings of this study confirm the speculation of
Tsao8 that selection of bronchial biopsy fragments for non-
histologic genomic or proteomic analysis is a flawed strategy.
Histologic examination is necessary to confirm the presence
of tumor in any particular biopsy fragment, before this frag-
ment is used for such analysis. Even then, the amount of
tumor available for predictive molecular testing may be
severely limited. Microdissection may be required if the
proportion of tumor in test samples has to be increased. It is
also worth bearing in mind that the effects of the marked
heterogeneity, both at a morphologic and at a genomic and
proteomic level, demonstrated in particular by non-small cell
lung carcinomas, will be exacerbated by analysis of such tiny
samples of tumor.
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